Metabolic
Retatrutide (RETA Peptide)
Retatrutide 15mg, packed into a practical Peptide Pen format. Purita brings together research-grade standards, clear product details, convenient handling and an uncomplicated ordering experience for research customers.
€199.90 · 15mg
Available options
Product information
What it is Retatrutide (LY3437943) is a synthetic peptide that activates three different receptors: GIP, GLP-1 and glucagon. Having all three targets in one molecule gives researchers a way to study several connected areas of metabolic signaling at the same time. GIP and GLP-1 have plenty in common. Both are incretin hormones and both are involved in glucose-dependent insulin signaling. Glucagon brings something different to the picture, with links to hepatic glucose and lipid metabolism as well as energy expenditure. Together, these three targets give retatrutide a different receptor profile from dual GIP/GLP-1 agonists such as tirzepatide. What has been studied Human research on retatrutide has included several metabolic measures rather than a single endpoint. Body weight and waist circumference have been studied alongside glucose, insulin, HbA1c and lipid levels. One Phase 2 trial involved 338 adults with obesity or overweight who did not have diabetes. Results differed across the dose groups. At 48 weeks, the mean change in body weight was 24.2% in the 12mg group, compared with 2.1% with placebo. Other retatrutide groups showed smaller changes. The study also reported changes in several cardiometabolic measures. Those numbers need their original context. They come from a controlled clinical trial with defined participant groups a